论文部分内容阅读
为了探讨Bcl－2蛋白在头颈恶性肿瘤发生、发展中的作用及与抑癌基因P53的关系，采用免疫组化链霉菌素生物素技术（LSAB法），对90例头颈恶性肿瘤和20例良性病变组织中Bcl－2、P53蛋白进行了检测。结果显示；48.9％的头颈恶性肿瘤表达Bcl-2蛋白，而20例良性病变全部防性。Bcl－2在头颈鳞癌的表达率（59．6％）明显高于腺癌（34．8％）、末分化癌（33．3％）和恶性淋巴瘤（P＜0．05）。在P53阳性肿瘤中Bcl－2蛋白的表达率更高。Bcl－2蛋白的阳性率与肿瘤的临床分期和病理分级无关，而阳性细胞着色强度与临床分期密切相关（P＜0．01），随着疾病的进展着色逐渐增强。结论：bcl－2基因产物可能在头颈肿瘤，特别是头颈鳞癌的发生及发展中起着重要的作用。
In order to investigate the role of Bcl-2 protein in the occurrence and development of head and neck malignancy and its relationship with P53, immunohistochemical streptavidin biotin technology (LSAB method) was used in 90 cases of head and neck malignancy and 20 cases of benign Bcl-2 and P53 proteins were detected in the lesions. The results showed that 48.9% of head and neck malignancies expressed Bcl-2 protein while 20 cases of benign lesions were completely protective. The expression rate of Bcl-2 in head and neck squamous cell carcinoma (59.6%) was significantly higher than that in adenocarcinoma (34.8%), terminally differentiated carcinoma (33.3%), and malignant lymphoma (P<0.05). The expression of Bcl-2 protein was higher in P53-positive tumors. The positive rate of Bcl-2 protein was not related to the clinical stage and pathological grade of the tumor, but the positive cell staining intensity was closely related to the clinical stage (P<0.01), and the staining gradually increased as the disease progressed. Conclusion: The bcl-2 gene product may play an important role in the occurrence and development of head and neck tumors, especially head and neck squamous cell carcinoma.